Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1803-1812

  Damment, Stephen ^a   Secker, Roger ^a   Shen, Victor ^b   Lorenzo, Victor ^c   Rodriguez, Mariano ^d  

^a Shire Pharmaceuticals   (United Kingdom)

^b MDS Inc   (Canada)

^c University of Tenerife   (Spain)

^d Hospital Reina Sofa   (Spain)

Author keywords

bone disease; chronic kidney diseasemineral and bone disorder; FOSRENOL; lanthanum carbonate; phosphate binder

Indexed keywords

LANTHANUM CARBONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; LONG TERM CARE; MALE; MINERAL DEFICIENCY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; URINALYSIS;

ANIMALS; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; CALCIUM; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MINERALS; PHOSPHORUS; RATS; RATS, WISTAR;

EID: 79958123458     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq682     Document Type: Article

References (40)

1. Saydah S, Eberhardt M, Rios-Burrows N et al. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-. 2004. JAMA 2007; 297: 1767-1768.
2. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663. (Pubitemid 38392981)
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953. (Pubitemid 43924257)
4. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
5. Almaden Y, Canalejo A, Hernandez A et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976. (Pubitemid 26200048)
6. Almaden Y, Felsenfeld AJ, Rodriguez M et al. Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int 2003; 64: 2311-2317. (Pubitemid 37449568)
7. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540.
8. Moallem E, Kilav R, Silver J et al. RNA-Protein binding and posttranscriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253-5259. (Pubitemid 28108690)
9. Felsenfeld AJ, Rodriguez M. Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 1999; 10: 878-890. (Pubitemid 29149540)
10. Nagano N, Miyata S, Obana S et al. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2001; 16: 1870-1878. (Pubitemid 32821420)
11. Hutchison AJ, Barnett ME, Krause R et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008; 110: c15-c23.
12. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85: S73-S78. (Pubitemid 36605868)
13. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005; 64: 428-437. (Pubitemid 41819402)
14. Malluche HH, Siami GA, Swanepoel C et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008; 70: 284-295.
15. Yokozawa T, Zheng PD, Oura H et al. Animal model of adenineinduced chronic renal failure in rats. Nephron 1986; 44: 230-234. (Pubitemid 16002549)
16. Tamagaki K, Yuan Q, Ohkawa H et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 2006; 21: 651-659. (Pubitemid 43372910)
17. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-537. (Pubitemid 43164446)
18. Katsumata K, Kusano K, Hirata M et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450. (Pubitemid 36871915)
19. Koeda T,Wakaki K,Koizumi F et al. Early changes of proximal tubules in the kidney of adenine-ingesting rats, with special reference to biochemical and electron microscopic studies. Jpn J Nephrol 1988; 30: 239-246.
20. Damment SJ, Cox AG, Secker R. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? Toxicol Lett 2009; 188: 223-229.
21. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
22. Hruska KA, Mathew S, Lund R et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157. (Pubitemid 351915080)
23. Tallon S, Berdud I, Hernandez A et al. Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Kidney Int 1996; 49: 1441-1446. (Pubitemid 26166419)
24. Bover J, Rodriguez M, Trinidad P et al. Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 1994; 45: 953-961. (Pubitemid 24234710)
25. Behets GJ, Dams G, Vercauteren SR et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004; 15: 2219-2228. (Pubitemid 39031361)
26. Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int 1991; 40: 1063-1068.
27. Miller MA, Chin J, Miller SC et al. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 1998; 23: 257-266. (Pubitemid 28434670)
28. Ben-Dov IZ, Pappo O, Sklair-Levy M et al. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant 2007; 22: 362-368. (Pubitemid 46189878)
29. Nechama M, Ben-Dov IZ, Silver J et al. Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. Am J Physiol Renal Physiol 2009; 296: F795-F800.
30. Nagano N, Miyata S, Obana S et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003; 18: 2014-2023. (Pubitemid 37220306)
31. Oka Y, Miyazaki M, Takatsu S et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007; 11: 107-113. (Pubitemid 46449871)
32. De Santo NG, Frangiosa A, Anastasio P et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19: S108-S114. (Pubitemid 44420095)
33. Bronner F, Slepchenko BM, Pennick M et al. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008; 47: 543-552. (Pubitemid 351969828)
34. Behets GJ, Verberckmoes SC, Oste L et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830-1836. (Pubitemid 40577718)
35. Behets GJ, Gritters M, Dams G et al. Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 2005; 27: 475-484. (Pubitemid 40993699)
36. Bervoets AR, Oste L, Behets GJ et al. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone 2006; 38: 803-810. (Pubitemid 44498596)
37. Lacour B, Lucas A, Auchere D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-1069. (Pubitemid 41623331)
38. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809-2813. (Pubitemid 43251027)
39. Bervoets AR, Behets GJ, Schryvers D et al. Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney Int 2009; 75: 389-398.
40. Damment SJ, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett 2007; 171: 69-77 (Pubitemid 46990669)